{
    "nct_id": "NCT05608291",
    "official_title": "A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma",
    "inclusion_criteria": "1. All patients must be either stage IIB, IIC, III, or stage IV per American Joint Committee on Cancer (AJCC) 8th edition and have histologically confirmed melanoma that is completely surgically resected in order to be eligible as defined by the protocol\n2. Complete surgical resection must be performed within 12 weeks prior to randomization, and enrollment may occur only after satisfactory wound healing from the surgery\n3. All patients must have disease-free status documented by a complete physical examination and imaging studies within 4 weeks prior to randomization, as described in the protocol\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "1. Uveal melanoma\n2. Any evidence of residual disease after surgery by imaging, pathology, or cytology.\n3. Ongoing or recent (within 2 years) evidence of clinically significant autoimmune disease that required treatment\n4. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection, as described in the protocol\n5. Another malignancy that is currently progressing or that required active treatment in the past 5 years, as described in the protocol\n6. Participants with a history of myocarditis\n7. Adolescent patients (â‰¥12 to <18 years old) with body weight <40 kg\n\nNote: Other Protocol Defined Inclusion/ Exclusion Criteria Apply",
    "miscellaneous_criteria": "Key"
}